New CODP treatment gets FDA nod

Nov. 12, 2018

Mylan and Theravance Biopharma have won approval for their inhalable treatment, Yupelri. 

Designed as a maintenance treatment for patients with chronic obstructive pulmonary disease, Yupelri is the first-ever once-daily, nebulized bronchodilator approved by the FDA for COPD. 

Around 16 million Americans have COPD, and the companies say that 9-10 percent of patients prefer a nebulized product to treat the condition. 

The companies plan to launch Yupelri in the U.S. later this year.  

Read the full Reuters report.